

**May 30, 2023**

<b>BSE Limited</b> Corporate Relationship Department P.J. Towers, Dalal Street, Fort, Mumbai - 400 001	<b>National Stock Exchange of India Ltd.</b> Exchange Plaza, Bandra-Kurla Complex, Bandra ( East) Mumbai - 400 051
<b>Scrip Code : 506109</b>	<b>Symbol : GENESYS</b>

Dear Sir/Madam,

**Subject: Statement of Deviation or Variation or Utilization of funds raised under Preferential Issue - Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter and financial year ended March 31, 2023**

In compliance with the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Statement of Deviation or Variation or Utilization of funds raised through Preferential Issue by the Company for the quarter and financial year ended March 31, 2023 as reviewed by the Audit Committee.

You are requested to take the above on your records.

Thanking You,

Yours Faithfully,

For **Genesys International Corporation Limited**

Vineet Chopra  
Vice President - Legal & Company Secretary



**GENESYS<sup>SM</sup>**  
*Bringing together  
people and technology*

<b>Disclosure pursuant to SEBI (Listing Obligations &amp; Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/162/2019 dated December 24, 2019</b>	
Name of the Listed Entity	Genesys International Corporation Limited
Mode of Fund Raising	Public Issues / <del>Rights Issues</del> / Preferential Issues / QIP / Others
Date of Raising Funds	a) February 11, 2023 b) July 14, 2022 c) July 22, 2022
Amount Raised	a) Rs.6.86 crores - (on February 11, 2023) { 75% of the balance money received on issue of 7,50,000 convertible warrants}  b) Rs.48.75 crores (on July 14, 2022)  c) Rs.150.06 crores (on July 22, 2022)
Report filed for Quarter ended	March 31, 2023
Monitoring Agency, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	N.A
Explanation for the Deviation / Variation	N.A
Comments of the Audit Committee after review	None
Comments of the auditors, if any	Not applicable



**GENESYS<sup>SM</sup>**

*Bringing together  
people and technology*

**Objects for which funds have been raised and where there has been a deviation, in the following table**

Sr. no.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
a)	Combination of part funding of the capital expenditure, support growth plans of the company, working capital requirements, investment and general corporate purposes	N.A	Rs.6.86 crores	Nil	Rs. 6.86 crores	Nil	<p>1. The members of the Company on 31st July, 2021 had approved issue of 7,50,000 Warrant convertible into equity shares at price of Rs.122/-</p> <p>2. The Company received Rs.2,28,75,000/- i.e 25% of the issue price for allotment of warrants. The Company on 13th August, 2021 allotted 7,50,000 warrant convertible into equity shares.</p> <p>3. The Company received Rs.6,86,25,000/- i.e balance 75% of warrant money for conversion into equity shares. The Company on 11<sup>th</sup> February, 2023 allotted 7,50,000 equity shares.</p>



**GENESYS<sup>SM</sup>**  
*Bringing together  
 people and technology*

b)	Combination of part funding of the capital expenditure, support growth plans of the company, working capital requirements, investment and general corporate purposes or any combination thereof to pursue the business objects of the Company	N.A	Rs. 48.75 crores	Nil	Rs. 48.75 crores	Nil	<p>1. The members of the Company on 9th July, 2022 had approved issue of 3,19,145 Warrant convertible into equity shares at price of Rs.470/-</p> <p>2. The Company received Rs.3,74,99,537.50/- i.e 25% of the issue price for allotment of warrants. The Company on 14th July, 2022 allotted 3,19,145 warrant convertible into equity shares.</p> <p>3. The Company allotted 9,57,435 equity shares on 14th July, 2022 on receipt of Rs.44,99,94,450/-</p>
c)	Combination of part funding of the capital expenditure, support growth plans of the company, working capital requirements, investment	N.A	Rs. 150.06 crores	Nil	Rs. 129.64 crores	Nil	<p>1. The members of the Company on 9th July, 2022 had approved issue of 13,04,345 Warrant convertible into equity shares at price of Rs.460/-</p> <p>2. The Company received Rs.14,99,99,675/- i.e 25% of the issue price for allotment of warrants. The Company on 22nd July, 2022</p>



**GENESYS<sup>SM</sup>**

*Bringing together  
people and technology*

and general corporate purposes or any combination thereof to pursue the business objects of the Company							allotted 13,04,345 warrant convertible into equity shares.  3. The Company allotted 20,22,540 equity shares on 22nd July, 2022 on receipt of Rs.1,35,05,93,700/-
---	--	--	--	--	--	--	---

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the fund have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

**For Genesys International Corporation Limited**

**Vishnubhatla Ravikumar Jatavallabha**  
**Chief Financial Officer**

Date: 30.05.2023

Place: Mumbai